Sun Pharma Initiates Class II Recall of Lisdexamfetamine Dimesylate Capsules Due to Failed Dissolution Specifications
Sun Pharmaceutical Industries, Inc. has initiated a U.S. Nationwide Class II recall for specific lots of Lisdexamfetamine Dimesylate Capsules, 20 mg, manufactured by OHM Laboratories. This action stems from failed dissolution specifications observed during stability testing, posing significant compliance and supply chain risks for procurement and regulatory teams managing Lisdexamfetamine Dimesylate sourcing.
FDA Class II Recall: Failed Dissolution for Lisdexamfetamine Dimesylate Capsules
Sun Pharmaceutical Industries, Inc. has initiated a voluntary Class II recall, D-0145-2026, impacting specific lots of Lisdexamfetamine Dimesylate Capsules, 20 mg. This critical regulatory action, initiated on October 28, 2025, and reported to the FDA on November 5, 2025, stems from a fundamental quality control failure: out-of-specification (OOS) results observed in dissolution testing. Specifically, these failures were identified during analysis at the 12-month long-term stability station (25°C, 60%RH), indicating that the product's ability to release its active pharmaceutical ingredient (API) effectively degrades over time under specified storage conditions. For procurement directors, this means an immediate disruption to the supply of affected lots, namely AD42469 (expiring February 28, 2026) and AD48707 (expiring April 30, 2026), impacting U.S. Nationwide distribution. Regulatory affairs heads must recognize that dissolution failure directly compromises drug efficacy and patient safety, as the intended therapeutic effect of Lisdexamfetamine Dimesylate may not be achieved. This event signals a significant compliance breach, demanding a thorough review of quality agreements and supplier qualification processes for all generic stimulant medications.
Manufacturing and Distribution Chain Under Heightened Scrutiny
The recall of Lisdexamfetamine Dimesylate Capsules, 20 mg, places both the manufacturer, OHM Laboratories in New Brunswick, NJ 08901, and the distributor/recalling firm, Sun Pharmaceutical Industries, Inc. (operating from Cranbury, NJ 08512, and Princeton, NJ), under intense FDA scrutiny. While Sun Pharmaceutical Industries, Inc. is the recalling entity for product NDC 57664-047-88, the root cause points to manufacturing quality systems at OHM Laboratories. For supply chain VPs, this dual entity involvement complicates risk assessment; it necessitates evaluating not only Sun Pharma's distribution capabilities but also OHM Laboratories' manufacturing integrity for ANDA214484 and potentially other products. The Class II classification, indicating potential for temporary or reversible adverse health consequences, underscores the seriousness of the manufacturing defect. Business development executives should note that such recalls can erode market confidence and provide competitors with an opportunity to gain market share, particularly in the competitive generic Lisdexamfetamine Dimesylate segment. The incident mandates a re-evaluation of supplier diversification strategies to mitigate reliance on single manufacturing or distribution points for critical controlled substances.
Commercial Implications for the Lisdexamfetamine Dimesylate Market
This Class II recall directly impacts the availability of Sun Pharmaceutical Industries, Inc.'s generic Lisdexamfetamine Dimesylate Capsules, 20 mg, across the U.S. Nationwide market. As a human prescription drug administered orally, Lisdexamfetamine Dimesylate is a critical medication, and any supply disruption carries significant commercial weight. For procurement directors, the immediate consequence is the need to secure alternative supplies for the affected dosage form and potentially other strengths (as indicated by the broad range of associated NDCs like 57664-046 through 57664-052 and 57664-083 through 57664-088). Although the specific product quantity recalled is not available, the recall of two distinct lots with future expiry dates suggests a systemic issue rather than an isolated incident, potentially affecting future production batches. Regulatory affairs heads must prepare for increased scrutiny on all generic Lisdexamfetamine Dimesylate applications, as the FDA will likely intensify its focus on dissolution profiles and stability data. This event could prompt a re-evaluation of market entry strategies for new generic entrants, highlighting the stringent quality requirements for controlled substances and the commercial risks associated with non-compliance.
Forward Regulatory Outlook and Remediation Requirements for Sun Pharma
Following this voluntary Class II recall, Sun Pharmaceutical Industries, Inc. and OHM Laboratories face an imperative to conduct a comprehensive investigation into the root cause of the failed dissolution specifications for Lisdexamfetamine Dimesylate Capsules. For regulatory affairs heads, this means preparing for potential FDA follow-up inspections and the submission of robust Corrective and Preventive Actions (CAPA) plans. The firm must demonstrate that the manufacturing process, quality control procedures, and stability monitoring programs have been thoroughly reviewed and remediated to prevent recurrence. Failure to adequately address the underlying issues could lead to further regulatory actions, including potential Warning Letters, import alerts, or even consent decrees, particularly given the product's classification as a controlled substance (CII). Supply chain VPs should anticipate potential delays in future product releases from OHM Laboratories and Sun Pharmaceutical Industries, Inc. as these remediation efforts are undertaken and verified by the FDA. Proactive engagement with Sun Pharma to understand their remediation timeline and progress is crucial for maintaining supply chain continuity and mitigating future risks associated with their generic Lisdexamfetamine Dimesylate offerings.